MediBeacon was formed in 2012 specifically to acquire the optical diagnostic program from Mallinckrodt, the Pharmaceuticals business of Covidien. MediBeacon’s mission is to commercialize biocompatible optical diagnostic agents for physiological monitoring, surgical guidance, and imaging of pathological disease in the human population. Several product concepts in these arenas are contained in the MediBeacon Intellectual Property (IP) portfolio. The product pipeline includes real-time kidney function monitoring, a huge leap forward in the world of nephrology. The clinical history and road to FDA and European approvals on this component of the MediBeacon pipeline as well as other developments related to the platform of fluorescent agents and their potential clinical application.

MediBeacon was formed in 2012 specifically to acquire the optical diagnostic program from Mallinckrodt, the Pharmaceuticals business of Covidien. MediBeacon’s mission is to commercialize biocompatible optical diagnostic agents for physiological monitoring, surgical guidance, and imaging of pathological disease in the human population. Several product concepts in these arenas are contained in the MediBeacon Intellectual Property (IP) portfolio. The product pipeline includes real-time kidney function monitoring, a huge leap forward in the world of nephrology. The clinical history and road to FDA and European approvals on this component of the MediBeacon pipeline as well as other developments related to the platform of fluorescent agents and their potential clinical application.